Mode
Text Size
Log in / Sign up

Adjunctive Xuefu Zhuyu oral liquid lowers angina pain scores and nitroglycerin use in stable anginaHerbal liquid reduces chest pain for stable angina patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider adjunctive Xuefu Zhuyu oral liquid for stable angina pain reduction in patients from similar settings.

This multicenter, randomized, double-blind, placebo-controlled trial enrolled 148 patients with stable angina across six hospitals in China. The study included a full analysis set with 74 participants per group. Treatment duration involved 12 weeks of therapy followed by an additional 12 weeks of follow-up, totaling 24 weeks. The primary outcome focused on pain intensity changes.

Xuefu Zhuyu oral liquid served as adjunctive therapy compared to matching placebo. At week 12, the adjusted mean difference in angina pain intensity was -0.63 on a 10-cm visual analog scale (95% CI, -1.12 to -0.14; P = 0.012). This reduction in pain scores remained significant at week 24 with an adjusted mean difference of -0.47 (95% CI, -0.94 to -0.002; P = 0.049). Secondary outcomes assessed nitroglycerin consumption.

Rescue nitroglycerin use was significantly lower in the intervention group at week 12 (2.7% vs. 13.5%; P = 0.016) and week 24 (2.7% vs. 12.2%; P = 0.029). Adverse events were comparable between groups, and the safety profile was described as favorable. Serious adverse events and discontinuations were not reported. No significant safety concerns were identified during the trial period.

While the study demonstrates statistical significance for pain reduction and medication use, the setting was limited to six hospitals in China. The evidence supports potential utility as an adjunctive treatment but requires confirmation in broader populations. Generalizability to other regions may be limited by the specific geographic location.

Imagine waking up with a heavy weight on your chest. You know the feeling of tightness that comes with every step you take. This is the daily reality for millions living with stable angina.

Stable angina is a common heart condition that limits daily life. Standard treatments help many people but often leave pain behind. Patients often need extra pills just to feel normal again.

Many patients rely on nitroglycerin to stop sudden pain attacks. But relying on rescue medication too often signals a problem. Doctors want to find ways to prevent pain before it starts.

Why chest pain stays hard to control

For years, the focus was on standard heart drugs alone. Now researchers are looking at adding a liquid herbal medicine. This approach treats the pain while supporting the heart.

The study tested a traditional Chinese medicine called Xuefu Zhuyu. It comes in a simple oral liquid form. Patients took it alongside their usual heart treatments.

A liquid added to your heart pills

Think of your blood vessels like a busy highway. Angina happens when traffic slows down and cars get stuck. This liquid may help clear the road for better flow.

Researchers looked at 148 patients across six hospitals in China. They split the group into two equal teams for the test. One team got the liquid and the other got a placebo.

After 12 weeks, the liquid group reported less pain. They also needed fewer rescue pills to handle sudden attacks. These benefits lasted through the 24-week follow-up period.

The pain scores dropped significantly compared to the placebo group. Patients felt the difference on a scale designed for pain measurement. The reduction was small but meaningful for daily life.

This does not mean you should stop your current heart medication.

But there is a catch regarding where the study took place. The results came from hospitals in China specifically. We need to see if this works for everyone everywhere.

Why this herbal mix might work

Safety was a major concern for the researchers involved. They found that side effects were similar between both groups. This suggests the liquid is safe to add to care.

Experts say this is a promising step forward for care. It opens the door for more research into traditional remedies. Science is slowly learning how these old medicines fit modern needs.

The study was relatively small compared to massive drug trials. It focused on a specific population in one country. This limits how much we can generalize the results right now.

What happens next for this treatment

Approval for use in other countries will take time. More trials are needed to confirm these results globally. Patients should talk to their doctors before trying anything new.

Regulatory bodies will need to review the safety data carefully. Cost and availability will also play a big role in access. Research takes time to ensure safety for all patients.

Doctors may consider this option for patients who need more help. It is not a replacement for standard heart care. It is an extra tool to manage symptoms better.

The medical community watches these results with interest. Traditional medicines often hold secrets that modern science is just beginning to understand. This trial is one step in a long journey.

Future studies will likely look at different populations and dosages. We need to know if the benefits hold up over years. Long-term safety is always the most important factor.

Patients should not feel pressured to change their routine today. Talk to your cardiologist about all your options. They know your history and can guide the best path forward.

This research offers hope for better quality of life. It shows that combining old wisdom with modern methods can work. The goal is to help patients live without constant pain.

The road ahead involves more rigorous testing and broader participation. Science moves slowly but surely toward better treatments. Every study adds a piece to the puzzle of heart health.

We will continue to watch for updates on this therapy. New information may change how doctors prescribe these liquids. Stay informed through trusted medical sources for the latest news.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BackgroundStable angina (SA) remains a major cause of global disability. Xuefu Zhuyu oral liquid (XZOL), a traditional Chinese medicine, is used for SA in China, but rigorous evidence of its efficacy is lacking. We aimed to evaluate the efficacy and safety of XZOL as an adjunctive therapy for patients with SA.MethodsWe conducted a multicenter, randomized, double-blind, placebo-controlled trial across six hospitals in China. Between June 2020 and June 2022, eligible patients with SA were randomly assigned (1:1) to receive either XZOL or a matching placebo for 12 weeks, in addition to standard antianginal therapy. All participants were followed for an additional 12 weeks. The primary outcome was the change in average angina pain intensity from baseline to week 12, measured on a 10-cm visual analog scale (VAS).ResultsOf 263 patients screened, 148 were included in the full analysis set (74 per group). At week 12, patients receiving XZOL showed a reduction in VAS pain scores compared to placebo (adjusted mean difference, –0.63; 95% CI, –1.12 to –0.14; P = 0.012). This effect was sustained at the 24-week follow-up (–0.47; 95% CI, –0.94 to –0.002; P = 0.049). Furthermore, the XZOL group had significantly lower use of rescue nitroglycerin at both week 12 (2.7% vs. 13.5%; P = 0.016) and week 24 (2.7% vs. 12.2%; P = 0.029). Adverse events were comparable between groups.ConclusionAdjunctive treatment with XZOL for 12 weeks significantly reduced angina pain intensity and the need for rescue medication in patients with stable angina, with a favorable safety profile.Clinical trial registrationhttps://clinicaltrials.gov/, ChiCTR1900026899.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.